医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

WEST CHESTER, Pa.

Molecular Targeting Technologies, Inc. (MTTI) and National Health Research Institutes (NHRI), Taiwan announced today that they will present results on a new cancer therapeutic at the American Association of Cancer Research conference (AACR) in Philadelphia. This small molecule drug conjugate has successfully achieved proof-of-concept in preclinical models and is now moving toward the next major milestone, which is the production of a drug product for non-clinical and clinical studies.

This technology is based on the discovery that dipicolylamine (DPA) derivatives are effective in delivering therapeutic agents to targeted disease sites that have phosphatidylserine exposed on the external surfaces of the cell membranes.

Chuan Shih, Ph.D., Director of Institute of Biotechnology and Pharmaceutical Research (IBPR) of NHRI said, “We are delighted to have this opportunity to work with MTTI and apply the unique DPA technology as a novel and specific delivery system for the development of novel cancer therapeutics.”

Chris Pak, President and CEO of MTTI said, “We are greatly encouraged by the robust activities and distinct advantage of this novel class of DPA-drug compared to conventional therapeutic agents in colon and pancreatic cancer models. We are assessing the effectiveness of this new therapeutic agent in other tumors as well.”

National Health Research Institutes

NHRI established in January 1996, is an autonomous research organization under the supervision and support of the government. NHRI is dedicated to improve the health and well-being of the people, enhance the quality of biomedical research and medical care, develop medical and pharmaceutical technology as well as train and cultivate biomedical researchers. Research units including 7 institutes, 3 centers and 1 division and core facilities such as Cell Bank, Digital Library and Bioinformatics are set up for state-of-the-art medical research. Scientists at NHRI conduct mission-oriented medical research and investigate many aspects of the basic biomedical sciences, as well as specific diseases. These range from the common problems such as aging, cancer, infectious diseases, mental disorders, occupational diseases to health policy.

Molecular Targeting Technologies, Inc.

MTTI is a privately held biotechnology company focused on the development of novel technologies for treatment and diagnosis of human diseases. MTTI has two platforms: (i) novel cancer therapeutics, and (ii) in vivo imaging agents.